Education
About Us
Working with TipRanks
Follow Us
Quoin Pharmaceuticals (QNRX)
NASDAQ:QNRX
Top Page
Quoin Pharmaceuticals
(NASDAQ:QNRX)
25Underperform
Positive Factors
Efficacy
Additional positive data shows significant improvement in patients treated twice daily with QRX003, supporting its efficacy in treating Netherton Syndrome.
Market Potential
An approved therapy for Netherton Syndrome has significant market potential as it remains a very difficult to treat disease with no approved disease-modifying therapeutic options.
Safety Profile
The absence of new safety concerns despite increased dosing of QRX003 positively supports its safety profile.
Negative Factors
Chronic Therapy Requirement
Discontinuation of QRX003 treatment reverses the treatment benefit, suggesting potential chronic use may be required for patients to maintain symptom relief.
Durability Concerns
Updated data showed that 4 weeks post-discontinuation of therapy, the patients’ symptom and disease severity scores returned essentially to baseline levels.
Symptom Relief Durability
The shares are trading down approximately 25% as some investors may be concerned that QRX003 did not maintain symptom relief durability or 'cure' patients.
Quoin Pharmaceuticals (QNRX) vs. S&P 500 (SPY)
Market Cap
$1.53M
Dividend YieldN/A
Average Volume (3M)237.68K
Price to Earnings (P/E)―
Beta (1Y)-0.03
Revenue GrowthN/A
EPS Growth42.26%
CountryUS
Employees3
SectorHealthcare
Sector Strength64
IndustryBiotechnology
Share Statistics
EPS (TTM)-81.73
Shares Outstanding588,167
10 Day Avg. Volume73,224
30 Day Avg. Volume237,676
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.00Price Target Upside-69.51% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Quoin Pharmaceuticals Business Overview & Revenue Model
Company DescriptionQuoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
How the Company Makes MoneyQuoin Pharmaceuticals generates revenue through the development and commercialization of its pharmaceutical products. The company's revenue model primarily involves the sale of its approved drugs and potential licensing agreements with other pharmaceutical firms. As Quoin continues to advance its product candidates through clinical trials, successful approvals and subsequent market launches are anticipated to be key revenue drivers. Additionally, the company may enter into strategic partnerships or collaborations that could provide milestone payments and royalties, further contributing to its earnings. Significant factors influencing its revenue include the successful development of its pipeline products, obtaining regulatory approvals, and the establishment of distribution networks for commercializing its therapies globally.
Quoin Pharmaceuticals Financial Statement Overview
Summary
Quoin Pharmaceuticals faces significant financial challenges, including zero revenue, consistent losses, and a heavy reliance on external financing. The company's precarious financial position is characterized by negative cash flow from operations and a lack of profitability.Income Statement
Quoin Pharmaceuticals has consistently reported zero revenue over the years, leading to negative net income, indicating a lack of operational profitability. The absence of revenue growth or positive margins highlights significant challenges in achieving financial stability.5
Very Negative
Balance Sheet
The company's balance sheet shows a positive equity position as of the latest report, primarily due to strong financing activities. However, the lack of revenue generation and historical negative equity and high liabilities present risks to financial stability and growth.25
Negative
Cash Flow
Quoin Pharmaceuticals struggles with negative operating and free cash flow, indicating difficulties in generating cash from operations. The reliance on financing to support cash flow needs raises concerns about long-term sustainability.15
Very Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 0.00 | -103.44K | -103.64K | -104.11K | -104.77K | EBIT |
| 0.00 | -9.38M | -8.85M | -20.37M | -2.05M | EBITDA |
| 0.00 | -9.27M | -8.74M | -21.37M | -2.01M | Net Income Common Stockholders |
| -8.96B | -8.69M | -9.28M | -8.52M | -1.76M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 3.62B | 10.69M | 12.85M | 7.48M | 323.83K | Total Assets |
| 15.71B | 12.17M | 14.46M | 9.36M | 1.38M | Total Debt |
| 0.00 | ― | ― | 743.84M | 1.21M | Net Debt |
| -3.62B | -2.40M | ― | 736.36M | 889.48K | Total Liabilities |
| 6.50B | 6.51M | 7.05M | 8.70M | 7.99M | Stockholders Equity |
| 9.20B | 5.66M | 7.41M | 657.03K | -6.61M |
| Cash Flow | Free Cash Flow | |||
| -7.86B | -7.86M | -8.73M | -6.35M | -1.46M | Operating Cash Flow |
| -7.86B | -7.86M | -8.48M | -5.72M | -1.34M | Investing Cash Flow |
| -1.89B | 2.19M | -10.15M | -625.00K | -125.00K | Financing Cash Flow |
| 10.97B | 5.22M | 14.01M | 13.50M | 1.79M |
Quoin Pharmaceuticals Technical Analysis
Negative
6.56
Price Trends
9.35
Negative
14.48
Negative
18.15
Negative
Market Momentum
-1.18
Negative
42.08
Neutral
45.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QNRX, the sentiment is Negative. The current price of 6.56 is below the 20-day moving average (MA) of 7.21, below the 50-day MA of 9.35, and below the 200-day MA of 18.15, indicating a bearish trend. The MACD of -1.18 indicates Negative momentum. The RSI at 42.08 is Neutral, neither overbought nor oversold. The STOCH value of 45.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QNRX.
Quoin Pharmaceuticals Risk Analysis
Quoin Pharmaceuticals disclosed 53 risk factors in its most recent earnings report. Quoin Pharmaceuticals reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Quoin Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $5.20B | 3.18 | -40.80% | 2.96% | 17.66% | 1.94% | |
44 Neutral | $3.54M | ― | -83.50% | ― | -11.94% | 56.72% | |
37 Underperform | $3.11M | ― | -153.55% | ― | -100.00% | 53.88% | |
34 Underperform | $3.35M | ― | -134.52% | ― | ― | 14.28% | |
29 Underperform | $3.54M | ― | -91.62% | ― | ― | 48.81% | |
27 Underperform | $3.30M | ― | -49.77% | ― | ― | 71.41% | |
25 Underperform | $1.53M | ― | -121.15% | ― | ― | 42.26% |
* Healthcare Sector Average
Performance Comparison
QNRX
Quoin Pharmaceuticals
6.56
-15.56
-70.34%
PALI
Palisade Bio
0.69
-5.66
-89.13%
GLMD
Galmed Pharmaceuticals
1.46
-3.34
-69.58%
INM
InMed Pharmaceuticals
2.93
-3.13
-51.65%
ARTL
Artelo Biosciences
1.03
-0.31
-23.13%
GLTO
Galecto
2.68
-14.10
-84.03%
Quoin Pharmaceuticals Earnings Call Summary
Earnings Call Date: Mar 13, 2025 | % Change Since: -36.86% | Next Earnings Date: May 7, 2025
Earnings Call Sentiment Positive
The earnings call reflects a generally positive outlook for Quoin Pharmaceuticals, with significant progress in clinical trials, strong commercial partnerships, and a solid financial position. However, challenges remain in managing cash burn and executing M&A strategies.Highlights
Transformational Year for Quoin
2023 was a transformational year for Quoin, marked by the release of the first-ever clinical data from a trial in Netherton syndrome subjects under an open IND with the FDA. The initial data was positive across several clinical endpoints with no safety signals.
Successful Protocol Amendments
The FDA cleared several protocol amendments, including increasing study sizes, changing dosing frequency, and lowering eligibility age to 14 years. These changes aim to generate more robust data sets and potentially expedite recruitment.
Strong Commercial Partnerships
Quoin has entered into 9 commercial partnerships covering 61 countries, which will facilitate a global launch of QRX003 once approved. This global network is unprecedented for a company of Quoin's size.
Positive Financial Position
Quoin completed a $6.5 million public offering, and entered an $8 million equity line of credit, extending the cash runway into the second half of 2026. The net loss decreased from $9.4 million in 2022 to $8.7 million in 2023.
Lowlights
Net Loss and Cash Burn
Despite a decrease in net loss from $9.4 million in 2022 to $8.7 million in 2023, Quoin still faces financial challenges with ongoing R&D expenses and a net loss of $2 million in Q4 2023.
Uncertainty in M&A Strategy
Quoin is actively seeking M&A opportunities but has not yet executed any deals. The company remains disciplined in its approach, focusing on late-stage orphan assets within the rare disease space.
Company Guidance
During the Q4 2023 earnings call for Quoin Pharmaceuticals (QNRX), key guidance included updates on clinical trials for QRX003, a potential treatment for Netherton syndrome. The company implemented several FDA-cleared protocol amendments, including increasing study size, altering dosing frequency, and lowering eligibility age to 14 years. They have 9 commercial partnerships covering 61 countries and completed a $6.5 million public offering, with an $8 million equity line of credit to extend their cash runway into the second half of 2026. Despite a net loss of $8.7 million for 2023, Quoin remains the only company with an open IND for Netherton syndrome, positioning itself for a pivotal year in 2024.Quoin Pharmaceuticals Corporate Events
Executive/Board ChangesShareholder Meetings
Quoin Pharmaceuticals Annual Meeting Approves Key Amendments
Neutral
Dec 10, 2024
Quoin Pharmaceuticals Ltd. held its 2024 Annual General Meeting where shareholders approved amendments to the company’s Articles of Association and compensation programs for key executives. These amendments align with Israeli regulations and Nasdaq rules, potentially impacting shareholder meeting protocols and executive compensation structures. The meeting also saw the election of directors, approval of changes to non-employee directors’ compensation, and the appointment of Marcum LLP as the company’s auditor, reflecting strategic governance and financial oversight adjustments.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.